Alfred F. Altomari
Net Worth

Last updated:

What is Alfred F. Altomari net worth?

The estimated net worth of Mr. Alfred F. Altomari is at least $9,834,550 as of 26 Aug 2022. He has received compensation worth at least $9,834,550 in Agile Therapeutics, Inc..

What is the salary of Alfred F. Altomari?

Mr. Alfred F. Altomari salary is $894,050 per year as Chairman & Chief Executive Officer in Agile Therapeutics, Inc..

How old is Alfred F. Altomari?

Mr. Alfred F. Altomari is 66 years old, born in 1959.

What stocks does Alfred F. Altomari currently own?

As insider, Mr. Alfred F. Altomari owns shares in one company:

Company Title Shares Price per share Total value
Agile Therapeutics, Inc. (AGRX) Chairman & Chief Executive Officer 64,343 $0 $0

What does Agile Therapeutics, Inc. do?

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX logo
AGRX
Agile Therapeutics, Inc.

Alfred F. Altomari insider trading

Agile Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 50,000 $0.45 $22,500
Purchase
Warrants (right to buy) 29,412 $0.85 $25,000
Purchase
Common Stock 58,824 N/A N/A
Purchase
Common Stock 26,200 $1.26 $33,091
Purchase
Common Stock 20,000 $1.61 $32,200
Purchase
Common Stock 12,500 $2 $25,025
Option
Common Stock 94,599 $1.76 $166,494
Option
Employee Stock Option (Right to Buy) 94,599 $1.76 $166,494
Option
Employee Stock Option (Right to Buy) 50,000 $1.76 $88,000
Option
Common Stock 50,000 $1.76 $88,000
Option
Employee Stock Option (Right to Buy) 16,541 N/A N/A
Option
Common Stock 16,541 $0.71 $11,744
Purchase
Common Stock 10,000 $2.71 $27,100
Purchase
Common Stock 20,000 N/A N/A
Purchase
Common Stock 25,000 N/A N/A
Option
Restricted Stock Units 35,314 N/A N/A
Option
Common Stock 35,314 N/A N/A
Option
Common Stock 16,667 N/A N/A
Option
Restricted Stock Units 16,667 N/A N/A
Purchase
Common Stock 10,000 $3.34 $33,400
Purchase
Common Stock 10,000 $3.51 $35,100
Option
Employee Stock Option (Right to Buy) 30,000 $1.76 $52,800
Option
Common Stock 30,000 $1.76 $52,800
Option
Common Stock 16,667 N/A N/A
Option
Restricted Stock Units 16,667 N/A N/A
Option
Restricted Stock Units 16,666 N/A N/A
Option
Common Stock 16,666 N/A N/A
Purchase
Common Stock 2,500 $8.73 $21,825
Option
Employee Stock Option (Right to Buy) 17,500 $1.76 $30,800
Option
Common Stock 17,500 $1.76 $30,800
Option
Common Stock 30,000 $1.76 $52,800
Option
Employee Stock Option (Right to Buy) 30,000 $1.76 $52,800

Agile Therapeutics key executives

Agile Therapeutics, Inc. executives and other stock owners filed with the SEC: